Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients
Not Applicable
Completed
- Conditions
- COVID-19 in hemodialysis patients
- Registration Number
- JPRN-UMIN000049684
- Lead Sponsor
- Fujita Memorial Hospital, Internal Medicine
- Brief Summary
After the third vaccination, 99.4% of the hemodialysis group and 100% of the control group were positive for antispike antibodies. Median antispike antibodies were 20,000 AU/mL (IQR, 7,729-37,000 AU/mL) in the hemodialysis group and 21,500 AU/ml (IQR, 14,000-32,250 AU/mL) in the healthcare worker group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 294
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of COVID-19 prior to study entry or with a positive blood test for anti-SARS-CoV-2 IgG antibodies at the time of study entry
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive rate of SARS-CoV-2 IgG antibody 2-3 weeks after 3 doses of BNT162b2 mRNA vaccine
- Secondary Outcome Measures
Name Time Method Analysis of factors involved in the elevation of SARS-CoV-2 IgG antibodies in mRNA vaccines